PBYI - Puma Biotechnology - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PBYI is currently covered by 2 analysts with an average price target of $14.29. This is a potential upside of $8.99 (169.62%) from yesterday's end of day stock price of $5.3.

Puma Biotechnology's activity chart (see below) currently has 142 price targets and 101 ratings on display. The stock rating distribution of PBYI is 92.31% BUY and 7.69% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 54.62% with an average time for these price targets to be met of 86.31 days.

Highest price target for PBYI is $7, Lowest price target is $7, average price target is $5.5.

Most recent stock forecast was given by EDWARD WHITE from HC WAINWRIGHT on 28-Feb-2025. First documented stock forecast 23-Jan-2015.

Currently out of the existing stock ratings of PBYI, 12 are a BUY (92.31%), 1 are a HOLD (7.69%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7

$3.71 (112.77%)

$7

5 months 16 days ago
(28-Feb-2025)

0/17 (0%)

$3.42 (95.53%)

Hold

$4

$0.71 (21.58%)

$7

1 years 9 months 10 days ago
(03-Nov-2023)

4/9 (44.44%)

$1.22 (43.88%)

92

Sell

$5

$1.71 (51.98%)

$6

3 years 9 months 8 days ago
(05-Nov-2021)

5/7 (71.43%)

$0.99 (24.69%)

261

Hold

$11

$7.71 (234.35%)

$11

3 years 10 months 16 days ago
(28-Sep-2021)

12/25 (48%)

$3.7 (50.68%)

191

Hold

$6

$2.71 (82.37%)

$13

4 years 7 days ago
(06-Aug-2021)

10/11 (90.91%)

$-1.1 (-15.49%)

129

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PBYI (Puma Biotechnology) average time for price targets to be met?

On average it took 86.31 days on average for the stock forecasts to be realized with a an average price target met ratio 54.62

Which analyst has the current highest performing score on PBYI (Puma Biotechnology) with a proven track record?

YIGAL NOCHOMOVITZ

Which analyst has the most public recommendations on PBYI (Puma Biotechnology)?

Yigal Nochomovitz works at CITI and has 24 price targets and 20 ratings on PBYI

Which analyst is the currently most bullish on PBYI (Puma Biotechnology)?

Thomas Shrader with highest potential upside - $126.71

Which analyst is the currently most reserved on PBYI (Puma Biotechnology)?

Michael Schmidt with lowest potential downside - -$0

Puma Biotechnology in the News

Puma (PBYI) Q2 Revenue Rises 11%

Key Points Non-GAAP EPS was $0.15, beating the non-GAAP estimate of $0.09 and turning positive on a GAAP basis from a loss in Q2 2024. Revenue rose to $52.4 million, an increase of approximately 11.3% compared to Q2 2024 and slightly above expectations.These 10 stocks could mint the next wave of millionaires › Puma Biotechnology(NASDAQ:PBYI),...

Puma anticipates $192M–$198M NERLYNX revenue for 2025 as company advances alisertib trials

Earnings Call Insights: Puma Biotechnology (PBYI) Q2 2025 MANAGEMENT VIEW * Alan H. Auerbach, CEO, reported total revenue for the second quarter of 2025 of $52.3 million, including product revenue net of $49.2 million from NERLYNX sales and $3.2 million in royalties. “Product revenue net was $49.2 million in the second quarter of 2025, an...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?